Earlier preclinical data showed that enzyme replacement therapy with Enobia’s product ENB-0040, significantly increases survival and prevents bone hypomineralization associated with hypophosphatasia, a rare genetic bone disease.
In these studies, subcutaneous administration of ENB-0040 was shown to significantly improve survival and prevent skeletal and dental manifestations of the disease.
Isabelle Lemire, associate director of non-clinical studies at Enobia Pharma, said: “We are extremely pleased to see evidence that enzyme replacement therapy with ENB-0040 may help repair skeletal damage caused by hypophosphatasia, as well as prevent the onset of dangerous bone hypomineralization.
“We look forward to advancing our clinical studies and confirming these results in patients with this deadly disease who currently have no approved treatment options.”